Although the exploration of mechanisms leading to myosteatosis and sarcopenia in NASH (such as specific muscle insulin resistance) and the plausible consequences on muscle secretome go beyond the diagnostic scope of this paper, investigating whether a muscle‐to‐liver axis operates in NAFLD pathophysiology19 could bring new mechanistic insights of high significance for therapeutic development. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.